BioMedWire Stocks

Why it is Important to Ensure the Stability of Medicare Advantage

About 34 million Americans are enrolled in Medicare Advantage plans and these older people as well as people with disabilities depend on these plans to get access to quality healthcare at an affordable cost. MA plans offer additional coverage, such as dental care, preventive screenings, transportation assistance and other such care that is critical for maintaining the health of these seniors.

Recently, the CMS approved a 4.33 percent increase in the payment for MA plans with effect from 2026. This increase means approximately $21 billion will be added to the funds available to support MA plans, something that will go a long way towards ensuring that seniors keep getting the medical care that they need despite rising costs of healthcare.

In addition to ensuring affordability, MA also increases access. Research shows Latino and Black enrollees of MA plans say they face fewer barriers to healthcare on account of the costs involved. This improved access reduces the racial and socioeconomic disparities in accessing needed medical services.

Seniors usually require specialized care because of the chronic health conditions, such as heart disease, that they live with. MA plans help these individuals to have some predictability in terms of the costs they are expected to incur to receive the care they need. Otherwise, their out-of-pocket expenses would fluctuate wildly or spiral out of control, leading to significant difficulties in receiving the care that they need.

It is therefore commendable that the recent changes made to Medicare are tailored to provide stability in these plans so that beneficiaries continue to get the healthcare they require. Future changes also need to be premised on the need to ensure continuity of the plans without creating any uncertainty for seniors. The reality is that most seniors depend on a fixed income (pension or withdrawals from their retirement savings) and any healthcare cost increases can easily make these individuals face financial challenges that prevent them from affording the costs involved in maintaining their health.

Policymakers at all levels therefore need to ensure that the long-term stability of Medicare Advantage is protected so that the people who rely on these plans can continue benefiting from them. The lives of millions of people depend on this, and the number of beneficiaries keeps increasing with each passing year.

This continuity also helps policy providers like Astiva Health to keep doing what they do to improve healthcare access for minorities in the communities that they serve.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035

The global market for brain tumor treatments is experiencing significant transformation powered by advances in…

2 days ago

New Blood Test Shows Potential in Revolutionizing Early Parkinson’s Detection

A team of researchers has developed a “cost-effective” and simple blood test with the potential…

4 days ago

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…

4 days ago

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…

5 days ago

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…

1 week ago

Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…

1 week ago